Diabetes: RAS inhibition: Probably not a one-size-fits-all approach

Drazenka Pongrac Barlovic; Mark E. Cooper

doi:10.1038/nrneph.2009.189

Diabetes: RAS inhibition: Probably not a one-size-fits-all approach

Drazenka Pongrac Barlovic, Mark E. Cooper

Research output: Contribution to journal › Short Survey › Research › peer-review

1 Citation (Scopus)

Abstract

Blockade of the reninangiotensin system does not seem to prevent early nephropathy in individuals with type 1 diabetes who are normoalbuminuric and normotensive, but both the angiotensin-converting-enzyme inhibitor enalapril and the angiotensin-receptor blocker losartan seem to retard retinopathy.

Original language	English
Pages (from-to)	669-670
Number of pages	2
Journal	Nature Reviews Nephrology
Volume	5
Issue number	12
DOIs	https://doi.org/10.1038/nrneph.2009.189
Publication status	Published - Dec 2009
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/nrneph.2009.189

Cite this

@article{91a46e5afc9742ab8f22ee2579f51280,

title = "Diabetes: RAS inhibition: Probably not a one-size-fits-all approach",

abstract = "Blockade of the reninangiotensin system does not seem to prevent early nephropathy in individuals with type 1 diabetes who are normoalbuminuric and normotensive, but both the angiotensin-converting-enzyme inhibitor enalapril and the angiotensin-receptor blocker losartan seem to retard retinopathy.",

author = "Barlovic, {Drazenka Pongrac} and Cooper, {Mark E.}",

year = "2009",

month = dec,

doi = "10.1038/nrneph.2009.189",

language = "English",

volume = "5",

pages = "669--670",

journal = "Nature Reviews Nephrology",

issn = "1759-5061",

publisher = "Nature Publishing Group",

number = "12",

}

TY - JOUR

T1 - Diabetes

T2 - RAS inhibition: Probably not a one-size-fits-all approach

AU - Barlovic, Drazenka Pongrac

AU - Cooper, Mark E.

PY - 2009/12

Y1 - 2009/12

N2 - Blockade of the reninangiotensin system does not seem to prevent early nephropathy in individuals with type 1 diabetes who are normoalbuminuric and normotensive, but both the angiotensin-converting-enzyme inhibitor enalapril and the angiotensin-receptor blocker losartan seem to retard retinopathy.

AB - Blockade of the reninangiotensin system does not seem to prevent early nephropathy in individuals with type 1 diabetes who are normoalbuminuric and normotensive, but both the angiotensin-converting-enzyme inhibitor enalapril and the angiotensin-receptor blocker losartan seem to retard retinopathy.

UR - http://www.scopus.com/inward/record.url?scp=73849136377&partnerID=8YFLogxK

U2 - 10.1038/nrneph.2009.189

DO - 10.1038/nrneph.2009.189

M3 - Short Survey

C2 - 19935810

AN - SCOPUS:73849136377

VL - 5

SP - 669

EP - 670

JO - Nature Reviews Nephrology

JF - Nature Reviews Nephrology

SN - 1759-5061

IS - 12

ER -

Diabetes: RAS inhibition: Probably not a one-size-fits-all approach

Abstract

UN SDGs

Access to Document

Other files and links

Cite this